Algernon Pharmaceuticals (AGNPF)
OTHER OTC:AGNPF
AGNPF Stock Chart & Stats
$0.05
$0.00(0.00%)
At close: 4:00 PM EST
$0.05
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.07
Previous CloseN/A
Volume93.00
Average Volume (3M)7.73K
Market Cap
$1.68M
Enterprise Value$1.54M
Total Cash (Recent Filing)$210.03K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.20
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,499,270
10 Day Avg. Volume2,484
30 Day Avg. Volume7,733
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.43
Enterprise Value/Ebitda-0.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt is a durable structural advantage for a clinical-stage biotech. It lowers fixed interest obligations, reduces bankruptcy and covenant risk, and gives management flexibility to allocate scarce cash to R&D or partnering. It also improves negotiating leverage when raising capital or structuring collaborations.
Improving Loss And Burn RatesA materially reduced net loss and lower cash burn demonstrates improving cost control and operational discipline. This durable trend can extend runway, lower near-term financing needs, and make partnerships or licensing deals more achievable versus peers that remain on higher burn trajectories.
Focused Clinical-stage R&D StrategyA strategy centered on repurposed and targeted novel therapeutics can shorten development timelines and reduce early-stage scientific risk versus wholly novel discovery. The company's emphasis on regulatory, manufacturing and partnering workstream aligns with a capital-efficient model that can attract collaborators and de-risk commercialization pathways.
Bears Say
Zero RevenueNo revenue is a fundamental constraint: without product sales the company cannot internally finance operations, validate commercial demand, or demonstrate recurring cash generation. This structural state forces reliance on external funding and keeps long-term sustainability contingent on successful clinical outcomes or partnering.
Persistent Negative Cash FlowConsistent negative operating and free cash flow is a durable liability: it necessitates recurrent capital raises, which can dilute shareholders and divert management focus. Even with improved burn, ongoing negative FCF constrains the ability to scale programs, invest in multiple assets, or respond to unforeseen clinical delays without external financing.
Clinical-stage, Binary Program RiskAs a pre-revenue clinical-stage firm, business fundamentals hinge on binary clinical and regulatory outcomes. Program failures or delays materially impair valuation and funding prospects. Structural dependence on successful trials and partner interest means long lead times to revenue and elevated execution risk compared with companies with commercial operations.
Algernon Pharmaceuticals News
AGNPF FAQ
What was Algernon Pharmaceuticals’s price range in the past 12 months?
Algernon Pharmaceuticals lowest stock price was $0.02 and its highest was $0.07 in the past 12 months.
What is Algernon Pharmaceuticals’s market cap?
Algernon Pharmaceuticals’s market cap is $1.68M.
When is Algernon Pharmaceuticals’s upcoming earnings report date?
Algernon Pharmaceuticals’s upcoming earnings report date is May 05, 2026 which is in 24 days.
How were Algernon Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Algernon Pharmaceuticals overvalued?
According to Wall Street analysts Algernon Pharmaceuticals’s price is currently Overvalued.
Does Algernon Pharmaceuticals pay dividends?
Algernon Pharmaceuticals does not currently pay dividends.
What is Algernon Pharmaceuticals’s EPS estimate?
Algernon Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Algernon Pharmaceuticals have?
Algernon Pharmaceuticals has 46,499,270 shares outstanding.
What happened to Algernon Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Algernon Pharmaceuticals?
Currently, no hedge funds are holding shares in AGNPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Algernon Pharmaceuticals
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―
Ownership Overview
Options Prices
Currently, No data available
---